



How to prepare and administer AGILUS®

(dantrolene sodium hemiheptahydrate)

For the treatment of malignant hyperthermia

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Norgine Pharmaceuticals Ltd on: Tel: +44 (0)1895 826 606 Email: medinfo@norgine.com



Please scan or click the QR code at the end of this document to access prescribing information.

In combination with adequate support measures, AGILUS® is indicated for the treatment of malignant hyperthermia in adults and children of all ages.

Job code: UK-EC-AGI-2400041 Date of preparation: December 2024

Preparation and administration summary

How to prepare AGILUS®

- Each vial should be reconstituted by adding 20 mL water for injections and shaking for approximately 1 minute, before inspecting for particulates. Further shaking may be necessary.
- Reconstituted AGILUS® does not need to be filtered prior to administration.

How to administer AGILUS®


1. A reconstituted vial of AGILUS® contains 120mg of dantrolene, with a final volume of 22.6 mL.¹
2. Reconstituted AGILUS® must not be mixed with other solutions or given via the same venous access.¹
3. The therapy is given rapidly by intravenous injection.¹

How to dose AGILUS®

In addition to treating the patient with AGILUS®, other supportive measures must be continued.

An initial dose of 2.5 mg/kg body weight for adult and paediatric patients. For all bodyweights, the initial dose and any repeat doses should not exceed 300 mg, equivalent to 2.5 vials, per round of treatment.¹

Further bolus doses of 2.5 mg/kg should be repeated every 10 minutes when the main clinical symptoms of MH are still present.



Suggested dose of AGILUS®

Dosing examples by body weight to achieve a loading dose of 2.5 mg/kg for both adults and children

Number of vials to be prepared ^a	Body weight range	Example dosing recommendation		
		Body weight	Dose to be administered	Volume to be administered ^a
1	Up to 48 kg	3 kg	7.5 mg	1.4 mL
		6 kg	15 mg	2.8 mL
		12 kg	30 mg	5.6 mL
		24 kg	60 mg	11.3 mL
		48 kg	120 mg	22.6 mL
2	From 49 kg to 96 kg	72 kg	180 mg	33.9 mL
		96 kg	240 mg	45.2 mL
3	From 97 kg	120 kg	300 mg	56.5 mL
		144 kg ^b	300 mg ^b	56.5 mL

a. Total volume of one reconstituted vial is 22.6mL
b. For all body weights, the initial dose and any repeat doses should not exceed 300 mg, equivalent to 2.5 vials

Continued monitoring of the patient is necessary, as the clinical features of malignant hyperthermia may recur within the first 24 hours.

If this occurs, AGILUS® should be re-administered at a dose of 2.5 mg/kg every 10 minutes until the signs of malignant hyperthermia stop.

If a cumulative dose of 10 mg/kg or above is needed, the diagnosis of malignant hyperthermia should be re-examined.

Prescribing information

Click or scan to view Prescribing information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Norgine Pharmaceuticals Ltd on:
Tel: +44 (0)1895 826 606 Email: medinfo@norgine.com

Please refer to the Summary of Product Characteristics for full details on preparation and administration.



Reference: 1. AGILUS. Summary of product characteristics